Literature DB >> 23565350

MicroRNAs in Liver Health and Disease.

Shu-Hao Hsu1, Kalpana Ghoshal.   

Abstract

MicroRNAs (miRNAs), a class of short non-coding RNAs, have been studied intensely and extensively in the past decade in every aspect of biological processes, including cell differentiation, proliferation and death. These findings pointed out the pivotal role of miRNA in posttranscriptional control of gene expression in animals and established miRNAs as therapeutic targets for different pathophysiological processes, including liver disease. Here we have discussed the recent advances made in identifying the miRNAs deregulated in different liver diseases such as obesity, hepatitis, alcoholic and nonalcoholic steatohepatitis, cirrhosis and hepatocellular carcinoma, as well as pathophysiological conditions such as developmental abnormality. We have specifically reviewed the role of miRNAs in these diseases and discussed critically potential impacts of these miRNAs as biomarkers and/or therapeutic targets in liver pathobiology in the clinical setting. Finally, we have highlighted the latest techniques or preclinical and/or clinical trials that are being developed to replenish or inhibit the deregulated miRNAs.

Entities:  

Keywords:  CC; Fibrosis; Gene therapy; HCC; Hepatitis; Hepatocellular carcinoma; Liver development; Liver disease; Metabolism; Pathobiology; miRNA; microRNA

Year:  2013        PMID: 23565350      PMCID: PMC3616382          DOI: 10.1007/s40139-012-0005-4

Source DB:  PubMed          Journal:  Curr Pathobiol Rep        ISSN: 2167-485X


  99 in total

1.  MicroRNA genes are transcribed by RNA polymerase II.

Authors:  Yoontae Lee; Minju Kim; Jinju Han; Kyu-Hyun Yeom; Sanghyuk Lee; Sung Hee Baek; V Narry Kim
Journal:  EMBO J       Date:  2004-09-16       Impact factor: 11.598

Review 2.  Gene therapy: regulations, ethics and its practicalities in liver disease.

Authors:  Xi Jin; Yi-Da Yang; You-Ming Li
Journal:  World J Gastroenterol       Date:  2008-04-21       Impact factor: 5.742

3.  Retrovirus-mediated RNA interference. Targeting hTERT through stable expression of short-hairpin RNA.

Authors:  Amanda P Cunningham; Lucy G Andrews; Trygve O Tollefsbol
Journal:  Methods Mol Biol       Date:  2007

4.  Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis.

Authors:  Katey J Rayner; Frederick J Sheedy; Christine C Esau; Farah N Hussain; Ryan E Temel; Saj Parathath; Janine M van Gils; Alistair J Rayner; Aaron N Chang; Yajaira Suarez; Carlos Fernandez-Hernando; Edward A Fisher; Kathryn J Moore
Journal:  J Clin Invest       Date:  2011-06-06       Impact factor: 14.808

5.  Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver.

Authors:  Shu-Hao Hsu; Bo Wang; Janaiah Kota; Jianhua Yu; Stefan Costinean; Huban Kutay; Lianbo Yu; Shoumei Bai; Krista La Perle; Raghu R Chivukula; Hsiaoyin Mao; Min Wei; K Reed Clark; Jerry R Mendell; Michael A Caligiuri; Samson T Jacob; Joshua T Mendell; Kalpana Ghoshal
Journal:  J Clin Invest       Date:  2012-07-23       Impact factor: 14.808

6.  MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells.

Authors:  Jakub Godlewski; Michal O Nowicki; Agnieszka Bronisz; Gerard Nuovo; Jeff Palatini; Michael De Lay; James Van Brocklyn; Michael C Ostrowski; E Antonio Chiocca; Sean E Lawler
Journal:  Mol Cell       Date:  2010-03-12       Impact factor: 17.970

7.  TLR4 enhances TGF-beta signaling and hepatic fibrosis.

Authors:  Ekihiro Seki; Samuele De Minicis; Christoph H Osterreicher; Johannes Kluwe; Yosuke Osawa; David A Brenner; Robert F Schwabe
Journal:  Nat Med       Date:  2007-10-21       Impact factor: 53.440

8.  Role of anti-oncomirs miR-143 and -145 in human colorectal tumors.

Authors:  Y Akao; Y Nakagawa; I Hirata; A Iio; T Itoh; K Kojima; R Nakashima; Y Kitade; T Naoe
Journal:  Cancer Gene Ther       Date:  2010-01-22       Impact factor: 5.987

Review 9.  Nanoparticle therapeutics: an emerging treatment modality for cancer.

Authors:  Mark E Davis; Zhuo Georgia Chen; Dong M Shin
Journal:  Nat Rev Drug Discov       Date:  2008-09       Impact factor: 84.694

10.  Dicer is essential for mouse development.

Authors:  Emily Bernstein; Sang Yong Kim; Michelle A Carmell; Elizabeth P Murchison; Heather Alcorn; Mamie Z Li; Alea A Mills; Stephen J Elledge; Kathryn V Anderson; Gregory J Hannon
Journal:  Nat Genet       Date:  2003-10-05       Impact factor: 38.330

View more
  12 in total

1.  MicroRNA-2053 overexpression inhibits the development and progression of hepatocellular carcinoma.

Authors:  Tao Song; Ke Ma; Cui Zhao; Jijin Yang; Jingyu Liu
Journal:  Oncol Lett       Date:  2019-06-20       Impact factor: 2.967

2.  Acute Hepatitis C Virus Infection Induces Consistent Changes in Circulating MicroRNAs That Are Associated with Nonlytic Hepatocyte Release.

Authors:  Ramy El-Diwany; Lisa N Wasilewski; Kenneth W Witwer; Justin R Bailey; Kimberly Page; Stuart C Ray; Andrea L Cox; David L Thomas; Ashwin Balagopal
Journal:  J Virol       Date:  2015-07-08       Impact factor: 5.103

Review 3.  miR-122 is a unique molecule with great potential in diagnosis, prognosis of liver disease, and therapy both as miRNA mimic and antimir.

Authors:  Sharda Thakral; Kalpana Ghoshal
Journal:  Curr Gene Ther       Date:  2015       Impact factor: 4.391

Review 4.  Differential Roles for Diploid and Polyploid Hepatocytes in Acute and Chronic Liver Injury.

Authors:  Patrick D Wilkinson; Andrew W Duncan
Journal:  Semin Liver Dis       Date:  2020-12-14       Impact factor: 6.115

Review 5.  Regulation and functional roles of chemokines in liver diseases.

Authors:  Sheng Cao; Mengfei Liu; Tejasav S Sehrawat; Vijay H Shah
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-05-11       Impact factor: 73.082

6.  Serum microRNAs as potential biomarkers of primary biliary cirrhosis.

Authors:  Youwen Tan; Tengli Pan; Yun Ye; Guohong Ge; Li Chen; Danfeng Wen; Shengqiang Zou
Journal:  PLoS One       Date:  2014-10-27       Impact factor: 3.240

7.  A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease.

Authors:  Youwen Tan; Guohong Ge; Tengli Pan; Danfeng Wen; Jianhe Gan
Journal:  PLoS One       Date:  2014-08-20       Impact factor: 3.240

Review 8.  The Role of miRNAs in Common Inflammatory Arthropathies: Osteoarthritis and Gouty Arthritis.

Authors:  Panagiota Papanagnou; Theodora Stivarou; Maria Tsironi
Journal:  Biomolecules       Date:  2016-11-11

9.  Reciprocal regulation of microRNA-122 and c-Myc in hepatocellular cancer: role of E2F1 and transcription factor dimerization partner 2.

Authors:  Bo Wang; Shu-hao Hsu; Xinmei Wang; Huban Kutay; Hemant Kumar Bid; Jianhua Yu; Ramesh K Ganju; Samson T Jacob; Mariia Yuneva; Kalpana Ghoshal
Journal:  Hepatology       Date:  2013-12-20       Impact factor: 17.425

10.  Effects of silybin supplementation on nutrient digestibility, hematological parameters, liver function indices, and liver-specific mi-RNA concentration in dogs.

Authors:  Maciej Gogulski; Adam Cieślak; Julia Grabska; Marie Ardois; Małgorzata Pomorska-Mól; Paweł A Kołodziejski; Kacper Libera; Viola Strompfová; Małgorzata Szumacher-Strabel
Journal:  BMC Vet Res       Date:  2021-06-26       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.